Erratum

In the paper "Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly" by M Borre *et al.*, Prostate Cancer and Prostatic Disease (1998), 1, 268-275, Table 3 was incorrect, the correct version is shown below.

Table 3 Cox-multivariate regression analyses including traditional markers, BCL-2 expression and Ki-67 score (including combinations) in all 221 prostate cancer patients irrespective clinical stage and in the 125 clinically localized prostate cancer patients using disease-specific death as end-point

	All 221 prostate cancer patients			125 clinically prostate cancer patients		
	P-value	RR	cnf.l. (95%)	P-value	RR	cnf.l. (95%)
A:						
T-class ^a	< 0.0001	1.97	1.60-2.41	0.08	—	—
M-class (M0 <i>vs</i> M1)	0.66	—	—	—	—	—
Grade ^b	0.014	1.37	1.06-1.76	0.005	1.62	1.16-2.28
BCL-2 (negative <i>vs</i> positive)	0.10	—	—	0.23	—	—
Ki-67 (low <i>vs</i> high)	0.02	1.53	1.06-2.21	0.10	—	—
B:						
T-class (T1a <i>vs</i> T1b <i>vs</i> T2)	< 0.0001	1.96	1.59-2.40	0.12	—	—
M-class (M0 <i>vs</i> M1)	0.37	—	—	—	—	—
Grade ^b	0.029	1.32	1.03-1.71	0.071	—	—
BCL-2 (negative <i>vs</i> positive)	0.68	—	—	0.22	—	—
Ki-67 (low <i>vs</i> high)	0.91	—	—	0.71	—	—
BCL-2/Ki-67 (neg/low <i>vs</i> others)	0.0001	0.40	0.24-0.66	0.0003	0.32	0.16-0.62
BCL-2/Ki-67 (pos/low <i>vs</i> others)	0.91	—	—	0.71	—	—
BCL-2/Ki-67(neg/high <i>vs</i> others)	0.68	—	—	0.22	—	—
BCL-2/Ki-67 (pos/high <i>vs</i> others)	0.77	—	—	0.38	—	—

RR: relative risk. Cnf.l.: confidence limit.

^a (T1a *vs* T1b *vs* T2 *vs* T > 2).

^b (well *vs* moderate *vs* poor).